Scisparc launches new jv targeting discovery of potential drugs for cancers and infectious diseases

Tel aviv, israel, march 10, 2022 /prnewswire/ -- scisparc ltd. (nasdaq: sprc) (the "company" or "scisparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the intended formation of a joint venture ("jv") to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions.
SPRC Ratings Summary
SPRC Quant Ranking